Table of Contents PART 01: EXECUTIVE SUMMARY PART 02: SCOPE OF THE REPORT PART 03: RESEARCH METHODOLOGY PART 04: INTRODUCTION • Market outline PART 05: MARKET LANDSCAPE • Market ecosystem • Market characteristics • Market segmentation analysis PART 06: MARKET SIZING • Market definition • Market sizing 2017 • Market size and forecast 2017-2022 PART 07: FIVE FORCES ANALYSIS • Bargaining power of buyers • Bargaining power of suppliers • Threat of new entrants • Threat of substitutes • Threat of rivalry • Market condition PART 08: PIPELINE LANDSCAPE PART 09: MARKET SEGMENTATION BY VACCINE TYPE • Overview • Comparison by vaccine type • Global live attenuated influenza vaccines market • Global recombinant influenza vaccines market • Market opportunity by vaccine type PART 10: MARKET SEGMENTATION BY AGE GROUP • Adults • Pediatrics PART 11: CUSTOMER LANDSCAPE PART 12: REGIONAL LANDSCAPE • Geographical segmentation • Regional comparison • Influenza vaccine market in Americas • Influenza vaccine market in EMEA • Influenza vaccine market in APAC • Market opportunity PART 13: DECISION FRAMEWORK PART 14: DRIVERS AND CHALLENGES • Market drivers • Market challenges PART 15: MARKET TRENDS • Strong pipeline • Strategic alliances PART 16: VENDOR LANDSCAPE • Overview • Landscape disruption PART 17: VENDOR ANALYSIS • Overview • Vendor classification • Market positioning of vendors • AstraZeneca • CSL • GlaxoSmithKline • Sanofi PART 18: APPENDIX • List of abbreviations List of Exhibits Exhibit 01: Parent market Exhibit 02: Global vaccine market: Segmentation Exhibit 03: Market characteristics Exhibit 04: Market segments Exhibit 05: Market definition: Inclusions and exclusions checklist Exhibit 06: Market size 2017 Exhibit 07: Validation techniques employed for market sizing 2017 Exhibit 08: Global influenza vaccine market 2017-2022 ($ millions) Exhibit 09: Global influenza vaccine market: Year-over-year growth 2018-2022 (%) Exhibit 10: Five forces analysis 2017 Exhibit 11: Five forces analysis 2022 Exhibit 12: Bargaining power of buyers Exhibit 13: Bargaining power of suppliers Exhibit 14: Threat of new entrants Exhibit 15: Threat of substitutes Exhibit 16: Threat of rivalry Exhibit 17: Market condition: Five forces 2017 Exhibit 18: Pipeline landscape by development phase Exhibit 19: Key clinical trials candidates of influenza vaccines Exhibit 20: Global influenza vaccine market by vaccine type 2017-2022 (%) Exhibit 21: Comparison by vaccine type Exhibit 22: Global live attenuated influenza vaccines market 2017-2022 ($ millions) Exhibit 23: Global live attenuated influenza vaccines market: Year-over-year growth 2018-2022 (%) Exhibit 24: Global recombinant influenza vaccines market 2017-2022 ($ millions) Exhibit 25: Global recombinant influenza vaccines market: Year-over-year growth 2018-2022 (%) Exhibit 26: Market opportunity by vaccine type Exhibit 27: Adult influenza vaccine products and their cost Exhibit 28: Pediatric influenza vaccine products and their cost Exhibit 29: Customer landscape Exhibit 30: Global influenza vaccine market by geography 2017-2022 (%) Exhibit 31: Regional comparison Exhibit 32: Influenza vaccine market in Americas 2017-2022 ($ millions) Exhibit 33: Influenza vaccine market in Americas: Year-over-year growth 2018-2022 (%) Exhibit 34: Top 3 countries in Americas Exhibit 35: Influenza vaccine market in EMEA 2017-2022 ($ millions) Exhibit 36: Influenza vaccine market in EMEA: Year-over-year growth 2018-2022 (%) Exhibit 37: Top 3 countries in EMEA Exhibit 38: Influenza vaccine market in APAC 2017-2022 ($ millions) Exhibit 39: Influenza vaccine market in APAC: Year-over-year growth 2018-2022 (%) Exhibit 40: Top 3 countries in APAC Exhibit 41: Market opportunity Exhibit 42: Distribution of influenza vaccine doses in US by season Exhibit 43: Steps for production of IIV Exhibit 44: Molecules in phase III with sponsors Exhibit 45: Vendor landscape Exhibit 46: Landscape disruption Exhibit 47: Vendor landscape Exhibit 48: Vendor classification Exhibit 49: Market positioning of vendors Exhibit 50: AstraZeneca: Overview Exhibit 51: AstraZeneca: Business segments Exhibit 52: AstraZeneca: Organizational developments Exhibit 53: AstraZeneca: Geographic focus Exhibit 54: AstraZeneca: Segment focus Exhibit 55: AstraZeneca: Key offerings Exhibit 56: AstraZeneca: Key customers Exhibit 57: CSL: Overview Exhibit 58: CSL: Business segments Exhibit 59: CSL: Organizational developments Exhibit 60: CSL: Geographic focus Exhibit 61: CSL: Segment focus Exhibit 62: CSL: Key offerings Exhibit 63: CSL: Key customers Exhibit 64: GlaxoSmithKline: Overview Exhibit 65: GlaxoSmithKline: Business segments Exhibit 66: GlaxoSmithKline: Organizational developments Exhibit 67: GlaxoSmithKline: Geographic focus Exhibit 68: GlaxoSmithKline: Segment focus Exhibit 69: GlaxoSmithKline: Key offerings Exhibit 70: GlaxoSmithKline: Key customers Exhibit 71: Sanofi: Overview Exhibit 72: Sanofi: Business segments Exhibit 73: Sanofi: Organizational developments Exhibit 74: Sanofi: Geographic focus Exhibit 75: Sanofi: Segment focus Exhibit 76: Sanofi: Key offerings Exhibit 77: Sanofi: Key customers

AstraZeneca, CSL, GlaxoSmithKline, Sanofi, Altimmune, BionVax, FluGen, FOLIA BIOTECH, Genentech, Green Cross, Medicago, Moderna Therapeutics, Novavax, Shijiazhuang Yiling Pharmaceutical, SK Chemicals, UNM Pharma, Vaccitech, Vaxart, Vaxine Pty, and Visterra.